QRG Capital Management Inc. Cuts Stock Holdings in Medpace Holdings, Inc. $MEDP

QRG Capital Management Inc. decreased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 71.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 934 shares of the company’s stock after selling 2,386 shares during the quarter. QRG Capital Management Inc.’s holdings in Medpace were worth $448,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in MEDP. AQR Capital Management LLC increased its stake in Medpace by 31.6% in the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after buying an additional 324,293 shares during the last quarter. Wasatch Advisors LP grew its holdings in shares of Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after acquiring an additional 24,625 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after acquiring an additional 85,517 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Medpace by 19.4% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock valued at $210,637,000 after acquiring an additional 60,883 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

NASDAQ:MEDP opened at $538.23 on Friday. The business has a fifty day simple moving average of $467.24 and a two-hundred day simple moving average of $496.03. Medpace Holdings, Inc. has a 1 year low of $306.70 and a 1 year high of $628.92. The company has a market capitalization of $15.37 billion, a P/E ratio of 33.83, a P/E/G ratio of 2.72 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same period in the previous year, the company posted $3.67 earnings per share. The business’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Royal Bank Of Canada reduced their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and increased their price target for the company from $490.00 to $515.00 in a research report on Tuesday. Barclays decreased their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. BMO Capital Markets lowered their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $469.17.

Insiders Place Their Bets

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares in the company, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.